Skip to main content
Premium Trial:

Request an Annual Quote

Harvard Bioscience s Q4 Revenues Lurch 2.4 Percent as Profit Turns to Loss

NEW YORK, March 3 (GenomeWeb News) - Harvard Bioscience reported yesterday a 2.4-percent increase in revenues and an 8.9-percent loss for the fourth quarter.

 

Revenues for the three months ended Dec. 31, 2005,inched up to 17.8 million from $17.4 million in the year-ago period.

 

R&D expenses for the fourth quarter decreased 2 percent to $700,000 from $875,000 in Q4 2004.

 

Harvard Bioscience posted an $8.9-million loss in the current fourth quarter compared with a $1.1-million profit year-over-year.

 

According to CEO Chane Graziano, Harvard Bioscience expects to generate revenues between $16.5 million and $17 million for the first quarter of 2006. For the full year 2006, the company expects to generate revenue between $70 million and $72 million.

 

As of Dec. 31, Harvard Bioscience had about $7.6 million in cash and cash equivalents.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.